BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15964286)

  • 1. The acceptability of self-administration of subcutaneous Depo-Provera.
    Lakha F; Henderson C; Glasier A
    Contraception; 2005 Jul; 72(1):14-8. PubMed ID: 15964286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depo-Provera use in an Australian metropolitan practice.
    Fraser IS; Dennerstein GJ
    Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.
    Cameron ST; Glasier A; Johnstone A
    Contraception; 2012 May; 85(5):458-64. PubMed ID: 22079602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
    Upadhyay UD; Zlidar VM; Foster DG
    Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contraceptive efficacy and safety of DMPA-SC.
    Jain J; Jakimiuk AJ; Bode FR; Ross D; Kaunitz AM
    Contraception; 2004 Oct; 70(4):269-75. PubMed ID: 15451329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceptability and discontinuation of Depo-Provera, IUCD and combined pill in Kenya.
    Sekadde-Kigondu C; Mwathe EG; Ruminjo JK; Nichols D; Katz K; Jessencky K; Liku J
    East Afr Med J; 1996 Dec; 73(12):786-94. PubMed ID: 9103686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.
    Prabhakaran S; Sweet A
    Contraception; 2012 May; 85(5):453-7. PubMed ID: 22079605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of injectable contraceptive users in a low-income population in Texas.
    Sangi-Haghpeykar H; Poindexter AN; Moseley DC; Bateman L; Reid ED
    Fam Plann Perspect; 1995; 27(5):208-11, 225. PubMed ID: 9104608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
    Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH;
    Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depo-Provera: use of a long-acting progestin injectable contraceptive in Turkish women.
    Aktun H; Moroy P; Cakmak P; Yalcin HR; Mollamahmutoglu L; Danisman N
    Contraception; 2005 Jul; 72(1):24-7. PubMed ID: 15964288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya.
    Ruminjo JK; Sekadde-Kigondu CB; Karanja JG; Rivera R; Nasution M; Nutley T
    Contraception; 2005 Aug; 72(2):138-45. PubMed ID: 16022854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
    Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
    Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and acceptability of depo-medroxyprogesterone acetate injection. As a method of contraception in Saudi Arabia.
    Sobande AA; Al-Bar HM; Archibong EI; Sadek AA
    Saudi Med J; 2000 Apr; 21(4):348-51. PubMed ID: 11533816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral density.
    Johnson CC; Burkman RT; Gold MA; Brown RT; Harel Z; Bruner A; Stager M; Bachrach LK; Hertweck SP; Nelson AL; Nelson DA; Coupey SM; McLeod A; Bone HG
    Contraception; 2008 Apr; 77(4):239-48. PubMed ID: 18342646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depot-medroxyprogesterone acetate: an update.
    Bakry S; Merhi ZO; Scalise TJ; Mahmoud MS; Fadiel A; Naftolin F
    Arch Gynecol Obstet; 2008 Jul; 278(1):1-12. PubMed ID: 18470526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Researcher explains status of Depo Provera. [Answer to question of Marienetta Blackwell].
    Greenspan A
    Contracept Technol Update; 1981 Mar; 2(3):35-6. PubMed ID: 12337540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depo Now: preventing unintended pregnancies among adolescents and young adults.
    Rickert VI; Tiezzi L; Lipshutz J; León J; Vaughan RD; Westhoff C
    J Adolesc Health; 2007 Jan; 40(1):22-8. PubMed ID: 17185202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Women's satisfaction, use, storage and disposal of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) during a randomized trial.
    Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
    Contraception; 2018 Nov; 98(5):418-422. PubMed ID: 29758176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depo-Provera: costs eat up clinic contraceptive budgets.
    Contracept Technol Update; 1999 Jan; 20(1):1-3. PubMed ID: 12349019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch?
    Thurman AR; Hammond N; Brown HE; Roddy ME
    J Pediatr Adolesc Gynecol; 2007 Apr; 20(2):61-5. PubMed ID: 17418388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.